![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
REFINING HER2 IHC ASSESSMENT GUIDED BY CAP REPORTING TEMPLATE: ENABLING ACCURATE CLASSIFICATION ACROSS SOLID TUMORS AND ADDRESSING INTRATUMORAL HETEROGENEITY
The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. [11,12] The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation. [11,12]
Achieving the Best Outcomes under COVID-19 Endemicity
The first coronavirus (CoV) outbreak occurred as severe acute respiratory syndrome CoV in 2003 in China, followed by the emergence of the Middle East respiratory syndrome CoV in 2012.
NEPA as an Effective Therapeutic Approach for Managing ADC-Induced Nausea and Vomiting
Nausea and vomiting are common adverse effects associated with antibody-drug conjugates (ADCs), significantly impacting patients’ quality of life (QoL) and treatment adherence.
